Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Adalimumab (Humira) for uveitis in paediatric patients – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Uveitis affects the lining of the eye. It is an inflammation that can lead to eye pain, eye redness, headaches, and visual problems that can become permanent. In many cases the cause of uveitis is unknown, but it is much more common in patients who are affected by a form of childhood arthritis called juvenile idiopathic arthritis (JIA).
Adalimumab is a drug that is already used to treat JIA. It is injected under the skin once every two weeks. Some studies have suggested that it could be effective in treating the uveitis associated with JIA in patients who haven't responded to the standard treatments for this condition.
If adalimumab is licensed for use in the UK, it could be a new treatment option for children and adolescents with uveitis associated with JIA who are not responding to standard drug treatments. Indexing Status Subject indexing assigned by CRD MeSH Adalimumab; Anti-Inflammatory Agents; Child; Humans; Uveitis Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000755 Date abstract record published 14/06/2016 |